Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05371093
Title Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Kite, A Gilead Company

follicular lymphoma


axicabtagene ciloleucel

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Fludarabine

Bendamustine + Rituximab

Lenalidomide + Rituximab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.